253196-37-1

Usage

Uses

Used in Organic Synthesis:
Ethyl 5-(aminomethyl)isoxazole-3-carboxylate, N-BOC protected is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique functional groups allow for selective reactions and the formation of diverse chemical structures.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Ethyl 5-(aminomethyl)isoxazole-3-carboxylate, N-BOC protected is used as a building block for the synthesis of biologically active compounds and potential drug candidates. Its reactivity and structural features enable the development of new chemical entities with therapeutic potential.
Used in Drug Discovery:
Ethyl 5-(aminomethyl)isoxazole-3-carboxylate, N-BOC protected is employed in drug discovery processes to explore its potential as a precursor for the development of novel pharmaceuticals. Its unique structure and reactivity contribute to the design and synthesis of new molecules with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Ethyl 5-(aminomethyl)isoxazole-3-carboxylate, N-BOC protected is utilized for the synthesis of compounds with potential medicinal properties. Its functional groups and protected amine allow for the creation of diverse chemical entities that can be further optimized for specific biological targets.

InChI:InChI=1/C12H18N2O5/c1-5-17-10(15)9-6-8(19-14-9)7-13-11(16)18-12(2,3)4/h6H,5,7H2,1-4H3,(H,13,16)

Upstream product

• 95080-93-6 ethyl chlorooximidoacetate 
• 92136-39-5 N-tert-Butoxycarbonyl-1-amino-3-propyne 
• 24424-99-5 di-tert-butyl dicarbonate 
• 14337-43-0 ethyl 2-chloro-2-(hydroxyimino)acetate 

Downstream Products

• 612511-84-9 Ethyl 5-(aminomethyl)isoxazole-3-carboxylate hydrochloride 
• 253196-38-2 5-aminomethyl-isoxazole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis of GluN2A-selective NMDA receptor antagonists with an electron-rich aromatic B-ring

Glutamatergic N-Methyl-D-aspartate (NMDA) receptors are heterotetrameric ion channels that can be comprised of different subunits. GluN2A subunit-containing NMDA receptors are associated with diseases like anxiety, depression, and schizophrenia. However,

PYRAZOLE COMPOUNDS AND USE THEREOF

The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.

Novel Compounds

There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

Synthesis and pharmacological profile of a series of 2,5-substituted-N,N-dimethyltryptamine derivatives as novel antagonists for the vascular 5-HT1B-like receptor

The coronary 5-HT1B-like receptor has been implicated in vasospasm and it is postulated that a 5-HT1B-like antagonist may block the detrimental action of 5-HT whilst not interfering with normal blood vessel function. The synthesis and pharmacological profile of a novel series of 2-(N-heteroaryl)carboxamido-5-substituted-N,N-dimethyltryptamine derivatives as silent (as judged by the inability of angiotensin II to unmask 5-HT1B-like receptor mediated agonist activity in the rabbit femoral artery), competitive and selective 5-HT1B-like receptor antagonists is described. Modifications to the 2-carboxamido sidechain as well as the 5-ethylene linked heterocycle are explored. N-Furfuryl-5-[2-(N-phthalimido)ethyl]-3-[2-(dimethylamino)ethyl]-1H-indole-2- carboxamide (34) was discovered which fulfilled our in vitro selection criteria and which had a favourable pharmacokinetic profile. Compound 34 showed good affinity (pKB = 7.38) for the vascular 5-HT1B-like receptor and greater than 125 fold selectivity over α1-adrenoceptor affinity. The selectivity of 34 and related compounds for the 5-HT1B-like receptor over other receptor subtypes is discussed and a mode of binding for this class of compound to a pharmacophore model is proposed. The Royal Society of Chemistry 1999.